AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23261143 — intervention group
Group type: EXPERIMENTAL
Intervention: CDM
Number of subjects: 122
Study 23261143 — intervention group
Group type: EXPERIMENTAL
Intervention: DEBs
Number of subjects: 122
Study 23261143 — intervention group
Group type: COMPARATOR
Intervention: DE
Number of subjects: 122
Study 23261143 — intervention group
Group type: EXPERIMENTAL
Intervention: CDM and DEBs
Number of subjects: 122
Study 23261143 — intervention group
Group type: EXPERIMENTAL
Intervention: DE, CDM, DEBs
Number of subjects: 122
Study 21874932 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) + plasma rich in growth factors (PRGF)
Number of subjects: 6
Study 21874932 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF)
Number of subjects: 6
Study 19817561 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushing virtual cigarettes
Number of subjects: 91
Study 19817561 — intervention group
Group type: COMPARATOR
Intervention: Grasping virtual balls
Number of subjects: 91
Study 17455733 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaptanib sodium (Macugen)
Number of subjects: 0
Study 17455733 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15456336 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg once daily for 10 days
Number of subjects: 0
Study 15456336 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose prulifloxacin 600 mg
Number of subjects: 0
Study 15456336 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 0
Study 11223108 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light (2500 lux)
Number of subjects: 40
Study 11223108 — intervention group
Group type: COMPARATOR
Intervention: Dim red light (50 lux)
Number of subjects: 40
Study 9237065 — intervention group
Group type: EXPERIMENTAL
Intervention: Occult Blood Bead (OBB) test
Number of subjects: 4970
Study 9237065 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroscopy
Number of subjects: 4970
Study 9237065 — intervention group
Group type: COMPARATOR
Intervention: Mass screening (OBB test and gastroscopy)
Number of subjects: 4970
Study 7643653 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-cut catheters
Number of subjects: 212
Study 7643653 — intervention group
Group type: COMPARATOR
Intervention: Standard catheters
Number of subjects: 212
Study 7643653 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 212
Study 2527134 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 13
Study 2527134 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylurea
Number of subjects: 13
Study 341739 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 4% eye drops
Number of subjects: 21
Study 31778265 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement training based on combined brain-machine interfaces and physiotherapy
Number of subjects: 30
Study 31778265 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial alpha desynchronization conditions its modulation during intervention
Number of subjects: 30
Study 31778265 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive shift of desynchronization toward the ipsilesional hemisphere
Number of subjects: 30
Study 31225636 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapies
Number of subjects: 0
Study 31225636 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 29130272 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulary change (addition of a high-potency statin)
Number of subjects: 1100682
Study 29130272 — intervention group
Group type: COMPARATOR
Intervention: Guideline change (ACC/AHA cholesterol guidelines)
Number of subjects: 1100682
Study 29130272 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulary change (addition of a high-potency atorvastatin)
Number of subjects: 1100682
Study 25720984 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveOne
Number of subjects: 42
Study 25720984 — intervention group
Group type: COMPARATOR
Intervention: ProTaper Universal
Number of subjects: 42
Study 25601294 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure treatment in three contexts
Number of subjects: 46
Study 25601294 — intervention group
Group type: COMPARATOR
Intervention: Exposure treatment in one context
Number of subjects: 46
Study 23392481 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 rounds of annual mass drug administrations (MDAs) with azithromycin
Number of subjects: 1600
Study 23392481 — intervention group
Group type: COMPARATOR
Intervention: Cessation rule for MDA if no infection at 6 or 18 months
Number of subjects: 1600
Study 20450359 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 15
Study 20450359 — intervention group
Group type: COMPARATOR
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 15
Study 20450359 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG
Number of subjects: 15
Study 20450359 — intervention group
Group type: COMPARATOR
Intervention: GTR
Number of subjects: 15
Study 18986393 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve sclerosis (AVS) group
Number of subjects: 62
Study 18986393 — intervention group
Group type: COMPARATOR
Intervention: Control group (without AVS)
Number of subjects: 62
Study 17402204 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination (BSE) program with initial instruction and 2 reinforcement sessions over 5 years.
Number of subjects: 266064
Study 17402204 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BSE instruction).
Number of subjects: 266064
Study 17402204 — intervention group
Group type: EXPERIMENTAL
Intervention: BSE group (instruction).
Number of subjects: 266064
Study 17402204 — intervention group
Group type: COMPARATOR
Intervention: BSE group and Control group comparison.
Number of subjects: 266064
Study 12650790 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual air insufflation
Number of subjects: 120
Study 12650790 — intervention group
Group type: COMPARATOR
Intervention: CO2 insufflation
Number of subjects: 120
Study 12650790 — intervention group
Group type: EXPERIMENTAL
Intervention: CT colonography
Number of subjects: 120
Study 12650790 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 120
Study 12650790 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel preparation
Number of subjects: 120
Study 12650790 — intervention group
Group type: EXPERIMENTAL
Intervention: Future testing preference
Number of subjects: 120
Study 10992311 — intervention group
Group type: EXPERIMENTAL
Intervention: Dural sac anteroposterior (AP) diameter of 10.2 mm at the L3-4, L4-5, or L5-S1 vertebral levels
Number of subjects: 66
Study 10992311 — intervention group
Group type: EXPERIMENTAL
Intervention: Herniated disc with an AP diameter of approximately 3 mm
Number of subjects: 66
Study 10992311 — intervention group
Group type: COMPARATOR
Intervention: Comparison of herniated disc AP diameters in symptomatic patients vs. asymptomatic controls
Number of subjects: 66
Study 9416634 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative priming conditions in Experiment 1
Number of subjects: 0
Study 9416634 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative priming conditions in Experiment 2
Number of subjects: 0
Study 8218682 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL immune serum globulin (ISG)
Number of subjects: 0
Study 8218682 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL immune serum globulin (ISG)
Number of subjects: 0
Study 3315600 — intervention group
Group type: EXPERIMENTAL
Intervention: AP-SAC 30U
Number of subjects: 25
Study 3315600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3315600 — intervention group
Group type: COMPARATOR
Intervention: Hospital administration
Number of subjects: 25
Study 3315600 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home injection
Number of subjects: 25
Study 26630416 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessment of absence of epidural fat
Number of subjects: 155
Study 26630416 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessment of presence of tortuous caudal nerves
Number of subjects: 155
Study 26630416 — intervention group
Group type: EXPERIMENTAL
Intervention: Grading of compression on preoperative MRI
Number of subjects: 155
Study 26734916 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR plus LLLT
Number of subjects: 33
Study 26734916 — intervention group
Group type: COMPARATOR
Intervention: GTR alone
Number of subjects: 33
Study 24583792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC)‐based vaccination with modified HLA‐class I p53 peptides (Arm 1)
Number of subjects: 16
Study 24583792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC)‐based vaccination with Th tetanus toxoid peptide (Arm 2)
Number of subjects: 16
Study 24583792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC)‐based vaccination with Th wild‐type p53‐specific peptide (Arm 3)
Number of subjects: 16
Study 24583792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC)‐based vaccination (all arms)
Number of subjects: 16
Study 24583792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC)‐based vaccination
Number of subjects: 16
Study 21763099 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrambler therapy
Number of subjects: 52
Study 21763099 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based drug management
Number of subjects: 52
Study 20451294 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection control education and training programme
Number of subjects: 1131
Study 20451294 — intervention group
Group type: COMPARATOR
Intervention: Usual practice continued
Number of subjects: 1131
Study 18379854 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic-coated sheaths (5 or 6 French)
Number of subjects: 200
Study 18379854 — intervention group
Group type: COMPARATOR
Intervention: Non-coated sheaths
Number of subjects: 200
Study 16039603 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy/Habit Reversal Training (ACT/HRT)
Number of subjects: 25
Study 16039603 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 25
Study 14679075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow-milk-free diet during last trimester of pregnancy
Number of subjects: 205
Study 14679075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk introduction between 3 and 6 months
Number of subjects: 205
Study 14679075 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic disease
Number of subjects: 205
Study 10773501 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (2.5 mg) and fentanyl (0.4 mg) in 40 ml of 0.125% bupivacaine
Number of subjects: 60
Study 10773501 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.4 mg fentanyl in 40 ml of 0.125% bupivacaine)
Number of subjects: 60
Study 10773501 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (2 mg) and fentanyl (0.4 mg) in 40 ml of 0.125% bupivacaine
Number of subjects: 60
Study 9053816 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg once-a-day
Number of subjects: 10
Study 9053816 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 20 mg
Number of subjects: 10
Study 7953031 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based care (Daily Living Programme, DLP)
Number of subjects: 189
Study 7953031 — intervention group
Group type: COMPARATOR
Intervention: Standard in-patient and later out-patient care (control)
Number of subjects: 189
Study 3501007 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-predominant formula
Number of subjects: 111
Study 3501007 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein-predominant formula
Number of subjects: 111
Study 3501007 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed infants
Number of subjects: 111
Study 27905499 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism treatment
Number of subjects: 541
Study 25369393 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 27
Study 25369393 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg
Number of subjects: 27
Study 22883658 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected music during initial radiotherapy treatment
Number of subjects: 100
Study 22883658 — intervention group
Group type: COMPARATOR
Intervention: No music during initial radiotherapy treatment (Control)
Number of subjects: 100
Study 20550556 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical intervention
Number of subjects: 0
Study 20550556 — intervention group
Group type: COMPARATOR
Intervention: Continued pharmacotherapy
Number of subjects: 0
Study 19063834 — intervention group
Group type: EXPERIMENTAL
Intervention: Yang deficiency constitution
Number of subjects: 110
Study 19063834 — intervention group
Group type: COMPARATOR
Intervention: Normal constitution
Number of subjects: 110
Study 15736890 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser alone (Group L: 10 pps, 200 mJ for 90 sec, n = 37)
Number of subjects: 16
Study 15736890 — intervention group
Group type: EXPERIMENTAL
Intervention: Local minocycline administration following laser treatment (Group LP, n = 33)
Number of subjects: 16
Study 15736890 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone‐iodine irrigation following laser treatment (Group LI, n = 33)
Number of subjects: 16
Study 15736890 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (Control Group C, n = 32)
Number of subjects: 16
Study 12525726 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD
Number of subjects: 73
Study 12525726 — intervention group
Group type: COMPARATOR
Intervention: TD
Number of subjects: 73
Study 12525726 — intervention group
Group type: COMPARATOR
Intervention: DD
Number of subjects: 73
Study 10730356 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with neck diseases
Number of subjects: 40
Study 10730356 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic subjects
Number of subjects: 40
Study 10730356 — intervention group
Group type: EXPERIMENTAL
Intervention: Interexaminer reliability
Number of subjects: 40
Study 9273227 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with arterial hypertension
Number of subjects: 36
Study 9273227 — intervention group
Group type: COMPARATOR
Intervention: Patients without arterial hypertension
Number of subjects: 36
Study 9273227 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 1670585 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (18 mu daily) and zidovudine (600 mg daily)
Number of subjects: 56
Study 6617065 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 180 mg/day twice a day
Number of subjects: 27
Study 6617065 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 180 mg/day three times a day
Number of subjects: 27
Study 6617065 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosing regimens (twice and three times a day)
Number of subjects: 27
Study 29247068 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐04236921 50 mg
Number of subjects: 249
Study 29247068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 29978322 — intervention group
Group type: EXPERIMENTAL
Intervention: r-batroxobin (2.5 BU/2.0 mL)
Number of subjects: 24
Study 29978322 — intervention group
Group type: EXPERIMENTAL
Intervention: r-batroxobin (5.0 BU/2.0 mL)
Number of subjects: 24
Study 29978322 — intervention group
Group type: EXPERIMENTAL
Intervention: r-batroxobin (10.0 BU/2.0 mL)
Number of subjects: 24
Study 29978322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28531663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic breakfast intervention (50-250 ml medium-chain triglyceride drink + 5-15 g amino acids) after overnight fast during radiotherapy.
Number of subjects: 40
Study 28531663 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete ketogenic diet during radiotherapy without fasting prior to RT fractions, supplemented with amino acids.
Number of subjects: 40
Study 28531663 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary advice for ketogenic diet or carbohydrate reduction).
Number of subjects: 40
Study 28531663 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention groups (1 and 2).
Number of subjects: 40
Study 28531663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention groups (1 and 2).
Number of subjects: 40
Study 24421303 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-month exercise intervention plus usual care
Number of subjects: 120
Study 24421303 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 120
Study 22244599 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Asthma Severity Index (CASI)
Number of subjects: 0
Study 22244599 — intervention group
Group type: EXPERIMENTAL
Intervention: CASI
Number of subjects: 0
Study 19349153 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval-load training (ILT)
Number of subjects: 42
Study 19349153 — intervention group
Group type: COMPARATOR
Intervention: Constant-load training (CLT)
Number of subjects: 42
Study 17447657 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidiabetic treatment with pioglitazone or glimepiride for 26 ± 2 weeks
Number of subjects: 151
Study 15217057 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated visual displays
Number of subjects: 116
Study 15217057 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom demonstration
Number of subjects: 116
Study 15217057 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional lecture
Number of subjects: 116
Study 11756064 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Zn/d for 14 d (Z group)
Number of subjects: 653
Study 11756064 — intervention group
Group type: EXPERIMENTAL
Intervention: 60000 retinol equivalents (200000 IU) vitamin A on day 14 (A group)
Number of subjects: 653
Study 11756064 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc plus vitamin A (ZA group)
Number of subjects: 653
Study 11756064 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup and placebo capsule (placebo group)
Number of subjects: 653
Study 10483386 — intervention group
Group type: EXPERIMENTAL
Intervention: IAN/IO injection followed by repeated IO injection of 0.9 ml of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 38
Study 10483386 — intervention group
Group type: COMPARATOR
Intervention: IAN/IO injection followed by mock IO injection
Number of subjects: 38
Study 8074256 — intervention group
Group type: EXPERIMENTAL
Intervention: norfloxacin in a single 800‐mg dose
Number of subjects: 154
Study 8074256 — intervention group
Group type: EXPERIMENTAL
Intervention: norfloxacin, 400 mg twice a day for three days
Number of subjects: 154
Study 8074256 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim (160 mg)‐sulfamethoxazole (800 mg) (TMP‐SMX), twice a day for three days
Number of subjects: 154
Study 8074256 — intervention group
Group type: EXPERIMENTAL
Intervention: norfloxacin
Number of subjects: 154
Study 8074256 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim (160 mg)‐sulfamethoxazole (800 mg) (TMP‐SMX)
Number of subjects: 154
Study 2530714 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulotroban (4 x 800 mg per day)
Number of subjects: 107
Study 2530714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 2530714 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulotroban
Number of subjects: 107
Study 196518 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.025 mg/70 kg body weight)
Number of subjects: 0
Study 196518 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (0.25 mg/70 kg body weight)
Number of subjects: 0
Study 196518 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 0
Study 196518 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 0
Study 196518 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil and Fentanyl
Number of subjects: 0
Study 30741684 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2599666 10 mg
Number of subjects: 4
Study 30741684 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2599666 25 mg
Number of subjects: 4
Study 30741684 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2599666 100 mg
Number of subjects: 4
Study 30741684 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2599666 200 mg
Number of subjects: 4
Study 30741684 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2599666 25 mg once-weekly for 12 weeks
Number of subjects: 4
Study 30741684 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2599666
Number of subjects: 4
Study 28452989 — intervention group
Group type: EXPERIMENTAL
Intervention: O/CMC/HA
Number of subjects: 80
Study 28452989 — intervention group
Group type: COMPARATOR
Intervention: HA
Number of subjects: 80
Study 25740607 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-BCAA
Number of subjects: 41
Study 25740607 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO
Number of subjects: 41
Study 25740607 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-LEU
Number of subjects: 41
Study 25740607 — intervention group
Group type: COMPARATOR
Intervention: PLC
Number of subjects: 41
Study 25740607 — intervention group
Group type: EXPERIMENTAL
Intervention: RE
Number of subjects: 41
Study 23837862 — intervention group
Group type: EXPERIMENTAL
Intervention: extensively hydrolysed whey formula (eWH)
Number of subjects: 116
Study 23837862 — intervention group
Group type: EXPERIMENTAL
Intervention: extensively hydrolysed casein formula (eCH)
Number of subjects: 116
Study 23837862 — intervention group
Group type: EXPERIMENTAL
Intervention: eWH with standard formula
Number of subjects: 116
Study 23837862 — intervention group
Group type: EXPERIMENTAL
Intervention: eCH with standard formula
Number of subjects: 116
Study 21762267 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufloxacin (Group Ruf, n=70)
Number of subjects: 138
Study 21762267 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin (Group Lev, n=68)
Number of subjects: 138
Study 19014837 — intervention group
Group type: EXPERIMENTAL
Intervention: LC15-0444 200 mg
Number of subjects: 60
Study 19014837 — intervention group
Group type: EXPERIMENTAL
Intervention: LC15-0444 600 mg
Number of subjects: 60
Study 19014837 — intervention group
Group type: EXPERIMENTAL
Intervention: LC15-0444 (various doses 25, 50, 100, 200, 400, 600 mg)
Number of subjects: 60